Brief: Gensight Biologics Confirms Efficacy And Safety Results At 3 Years In Reflect Phase III Clinical Trial With Lumevoq®

Gensight Biologics SA

13/03/2023 06:45

March 13 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS CONFIRMS SUSTAINED EFFICACY AND SAFETY
OF
BILATERAL LUMEVOQ® INJECTIONS AT 3-YEAR FOLLOW-UP OF REFLECT
PHASE III TRIAL
    * CONTINUOUS BENEFITS IN BILATERALLY TREATED PATIENTS WITH
+17 TO
+20 ETDRS LETTERS IMPROVEMENT VERSUS NADIR AT 3 YEARS
    * 62% OF BILATERALLY TREATED PATIENTS OFF-CHART AT BASELINE
MOVE
BACK TO ON-CHART TERRITORY AT 3 YEARS
    * GOOD SAFETY PROFILE CONFIRMED AT 3 YEARS

Source text for Eikon:  ID:nBw61PSXha 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))